Zymeworks Sees Encouraging Early Phase 1 Data for Antibody-Drug Conjugate (ZYME:NASDAQ)

Zymeworks sees encouraging early phase 1 data for antibody-drug conjugate (ZYME:NASDAQ)

Zymeworks' antibody-drug conjugate ZW-191 phase 1 data shows anti-tumor activity and safety in cancer patients. Read more here.

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, including...

Zymeworks reports Phase I data for ZW191 ADC

Zymeworks has announced preliminary Phase I results for the antibody-drug conjugate (ADC), ZW191, targeting folate receptor-alpha (FR⍺).The post Zymeworks reports Phase I data for ZW191 ADC appeared first on Clinical Trials Arena.

Zymeworks (NASDAQ: ZYME) reports 44% ORR in Phase 1 ZW191 study; data show safety

Phase 1 ZW191: 44% ORR overall; 64% in gynecologic cancers at 6.4–9.6 mg/kg. 41 patients; no serious treatment‑related AEs; dose optimization starts 4Q 2025.